The polyphenols will be produced using an innovative biotechnology for use in the cosmetics and nutrition industries.
As a first step, DIC and Debut will begin construction of a biomanufacturing facility in the United States in 2023, and will launch global sales for use in the cosmetics field via the DIC Group's distribution network in 2024.
Debut possesses outstanding enzyme discovery and design technologies, as well as an advanced biomanufacturing platform (precision fermentation and cell-free manufacturing) using these enzymes.
These technologies enable the selective and stable production of many rare, naturally derived organic compounds.
In July 2021, DIC and Debut began the joint development of a new method for synthesizing natural pigments.
Working together, the two companies achieved titers one-thousand times higher than those typically achieved by traditional fermentation methods.
DIC and Debut will now jointly produce and sell polyphenols, which have become increasingly popular in recent years, for use in cosmetics and nutrition.
Polyphenols are naturally occurring organic compounds commonly found in plants, from which they are extracted for use in such consumer products as cosmetics, where they are referred to as "natural extracts."
However, despite the promising performance of polyphenols, there have been significant challenges to commercialization due to unacceptably low yields (the amount that can be extracted is often small) and various cost considerations.
Debut's proprietary biomanufacturing technology overcomes these issues and enables the stable production of active ingredients with high levels of purity and concentration.
In comparison with conventional cosmetic ingredients such as vitamin C, initial evaluation with laboratory prototypes has confirmed numerous superior effects on the skin, including antioxidant, anti-inflammatory and anti-aging properties at the genetic level.
In addition, this biomanufacturing technology uses less than one-tenth of the water and land required by the conventional extraction process, and significantly reduces post-extraction waste generation.
The new polyphenols will thus easily meet the expectations of both cosmetic brand owners and consumers for sustainable ingredients and environment-friendly manufacturing processes.
DIC Corp. is one of the world's largest fine chemicals companies and the core of the DIC Group, a multinational organization comprising over 190 companies, including Sun Chemical Corp., in more than 60 countries and territories.
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval
Alphyn doses first patient in Phase 2b trial of Zabalafin Hydrogel in Australia
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
Organon acquires US rights to TOFIDENCE from Biogen
Dupixent receives approval in Japan as first biologic for COPD treatment
Celltrion adds STEQEYMA to Costco Member Prescription Program
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories